Literature DB >> 2648188

Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease.

J H Carter1, J G Nutt, W R Woodward, L F Hatcher, T L Trotman.   

Abstract

Reducing dietary protein improves the effectiveness of levodopa (LD) but the most effective distribution of a low-protein diet (0.8 g/kg) is unclear. We compared a 1.6 g/kg protein diet, a 0.8 g/kg diet with protein evenly distributed between meals, and a 0.8 g/kg diet with protein restricted to the evening meal in 5 parkinsonian patients with motor fluctuations. We monitored clinical response, plasma LD, and plasma large amino acids (LNAAs) hourly throughout the day. Mean "on" times were 51% (1.6 g/kg diet), 67% (0.8 g/kg evenly distributed), and 77% (0.8 g/kg restricted). Hourly averages of plasma LD did not differ between the diets. The mean plasma LNAAs were 732 nmol/ml (1.6 g/kg diet), 640 (0.8 g/kg distributed), and 542 (0.8 g/kg restricted), and the diurnal pattern reflected the distribution of protein intake. In conclusion, the amount and distribution of dietary protein affect clinical response to LD. These effects are not related to LD absorption but are explained by the variation in plasma LNAAs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2648188     DOI: 10.1212/wnl.39.4.552

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers.

Authors:  D R Robertson; I Higginson; B S Macklin; A G Renwick; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

3.  Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay R Riddle; Suzy A Griffin; Wenhua Chu; Suwanna Vangveravong; Janet Neisewander; Robert H Mach; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

4.  Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients.

Authors:  C Brefel; C Thalamas; S Rayet; A Lopez-Gil; K Fitzpatrick; S Bullman; D R Citerone; A C Taylor; J L Montastruc; O Rascol
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 5.  Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.

Authors:  M C Kurth
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

6.  Long-term Medical Treatment for Parkinson's Disease.

Authors:  John M. Bertoni; Jose-Luis Prendes; Pamela Sprenkle
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

Review 7.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

8.  Diet with LPP for renal patients increases daily energy expenditure and improves motor function in parkinsonian patients with motor fluctuations.

Authors:  Michela Barichella; Chiara Savardi; Andrea Mauri; Agnieszka Marczewska; Antonella Vairo; Cinzia Baldo; Arianna Massarotto; Sara Elisabetta Cordara; Gianni Pezzoli
Journal:  Nutr Neurosci       Date:  2007 Jun-Aug       Impact factor: 4.994

9.  Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease.

Authors:  Tuhin Virmani; Sirinan Tazan; Pietro Mazzoni; Blair Ford; Paul E Greene
Journal:  J Clin Mov Disord       Date:  2016-05-26

Review 10.  Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.

Authors:  Aravind Mittur; Suneel Gupta; Nishit B Modi
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.